Aceragen, Inc.

NasdaqCM:ACGN 株式レポート

時価総額:US$3.2m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Aceragen バランスシートの健全性

財務の健全性 基準チェック /26

Aceragen has a total shareholder equity of $57.3M and total debt of $733.0K, which brings its debt-to-equity ratio to 1.3%. Its total assets and total liabilities are $78.5M and $21.1M respectively.

主要情報

1.3%

負債資本比率

US$733.00k

負債

インタレスト・カバレッジ・レシオn/a
現金US$2.12m
エクイティUS$57.35m
負債合計US$21.14m
総資産US$78.49m

財務の健全性に関する最新情報

We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

Aug 24
We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully

May 11
We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully

Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?

Mar 07
Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?

Recent updates

Idera Pharmaceuticals completes acquisition of Aceragen

Sep 28

We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

Aug 24
We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully

May 11
We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully

Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?

Mar 07
Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?

When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?

Jan 31
When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?

Idera outlines capital requirement to move tilsotolimod toward commercialization in advanced melanoma

Jan 13

Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?

Dec 27
Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?

Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

Dec 27
Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

Idera Pharmaceuticals receives $5M in additional proceeds from private placement

Dec 15

We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

Nov 25
We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

Idera Pharma names new operations chief

Nov 17

Idera Pharmaceuticals EPS misses by $0.37

Oct 29

財務状況分析

短期負債: ACGN's short term assets ($5.6M) do not cover its short term liabilities ($17.9M).

長期負債: ACGN's short term assets ($5.6M) exceed its long term liabilities ($3.3M).


デット・ツー・エクイティの歴史と分析

負債レベル: ACGN has more cash than its total debt.

負債の削減: ACGN's debt to equity ratio has increased from 0.1% to 1.3% over the past 5 years.


貸借対照表


キャッシュ・ランウェイ分析

過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。

安定したキャッシュランウェイ: ACGN has less than a year of cash runway based on its current free cash flow.

キャッシュランウェイの予測: ACGN has less than a year of cash runway if free cash flow continues to grow at historical rates of 13.3% each year.


健全な企業の発掘